Article

Researchers Explore New T-Cell Therapy Method

Treatment shows promise in fighting lymphoma in early studies.

A new approach has been created with the potential to simultaneously speed up and improve the process of T-cell therapy, according to a recent study.

The study was conducted by researchers at the Fred Hutchinson Cancer Research Center and published in Nature Biotechnology.

T-cell therapy is a form of immunotherapy that uses a patient’s own T-cells that are engineered to carry new proteins that can attack cancer.

In the study, researchers used a special, small protein tag that could purify and track T-cells after they were engineered. This new approach was performed to examine its effects on a mouse model of lymphoma and on human cancerous cells in the laboratory.

Researchers believe that this new approach could improve current T-cell therapy methods by boosting the potency of cells; growing larger numbers of cancer fighting T-cells; adding a potential “kill switch” that can deactivate cells quickly in the event of toxic side effects; and cutting down the amount of time for immune cell processing from 14 to 20 days to 9 days or less.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards